

Submission Details	
Status	Accepted
Open Date	01/10/2021
Deadline Date	29/10/2021
Date Submitted	25/10/2021
Type	Performance In Delivering
NHS provider	North West Anglia NHS Foundation Trust

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
55726	19/EM/0141	260308	A multicenter, phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of bimekizumab in the treatment of subjects with active psoriatic arthritis	Number Agreed	1	1	Date Agreed	15/10/2020	0	16/07/2021	1	Recruitment Finished	
55737	20/ES/0094	1003413	A PHASE II, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-9545 COMPARED WITH PHYSICIAN'S CHOICE OF ENDOCRINE MONOTHERAPY IN PATIENTS WITH PREVIOUSLY TREATED ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVAN	Number Agreed	1	1	Date Agreed	01/02/2022	1	24/09/2021	1	Recruitment Finished	
55738	17/EE/0221	223856	A phase 2, 24-week, randomized, double-blind, placebo-controlled, multicenter study, with an 80-week treatment extension, to evaluate the efficacy and safety of CC-90001 in subjects with idiopathic pulmonary fibrosis	Number Agreed	1	1	Date Agreed	31/12/2020	1	23/07/2021	1	Withdrawn By Sponsor	
55740	18/LO/1843	232910	A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING ATEZOLIZUMAB (ANTI?PD-L1 ANTIBODY) IN COMBINATION WITH ADJUVANT ANTHRACYCLINE/TAXANE-BASED CHEMOTHERAPY VERSUS CHEMOTHERAPY ALONE IN PATIENTS WITH OPERABLE TRIPLE-NEGATIVE BREAST CANCER	Number Agreed	4	4	Date Agreed	27/12/2021	0	04/08/2021	0	Withdrawn By Host	Site withdrew due to treatment options of platinum based chemotherapy and treatment with a PARP inhibitor unavailable whilst on the study. Publications of recent studies show these are beneficial to patient group and site wishes to offer these.